The Co-Sponsor in the conduct of a Clinical Trial in Germany
Abstract
The sponsor is highly relevant in the conduct of clinical trials, both from a financial point of view and in terms of responsibility for study management. Until now, only one sponsor was designated as the primary contact for the conduct of clinical trials. The new regulation (EU) No 536/2014 allows the use of multiple sponsors, so-called co-sponsors. But this also raises new problems and questions for existing contracts and new contracts between sponsors, especially regarding the liability of one or more co-sponsors in the external as well as the internal relationship. This article highlights the issues arising from this amendment and clarifies the differences between a sponsor and a co-sponsor.
Downloads
References
https://health.ec.europa.eu/system/files/2016-11/ctqa_v11_0.pdf
2. Fuderer M. University professor as sponsor of a clinical trial according to the Medicines Act: LIT Verlag: Berlin; 2016.p.11.
3. Koyuncu A. Purpose of the law and definition, scope, § 4 In: Kügel W, Müller R-G, Hofmann H-P, editors. Medicines Act. 3ed. Munich: C.H. BECK; 2022. p. 149, recital 238-9.
4. Weinert L. The new co-sponsor: What needs to be taken into account? Medicines & Law. 2019;1:12.
5. Zuck R. §4. In: Zuck R, Dettling H-U, editors. AMG – Medicines Act Commentary. 1 ed. Cologne: Carl Heymanns Verlag; 2020. recital 517f.
6. Rehmann WA. Medicines Act (AMG) Commentary, §4. Munich: C.H.Beck Verlag; 2020. recitcal 8
7. EudraLex – Volume 10 – Clinical trials guidelines, „Questions & Answers Document “– Version 11.0 Q&A 2.3 [Internet]. European Commission; 2013 May 15 [cited 2024 Apr 12]. Available from:
https://health.ec.europa.eu/system/files/2016-11/ctqa_v11_0.pdf.
8. Brixius K, Frehse M. Pharmaceutical law in practice. Brixius K, Frehse M, editors. Frankfurt: PMI Verlag; 2007.
9. European Commission - No 3.8 of Proposal for a Regulation of the European Parliament and of the Council on clinical trials on medicinal products for human use, and repealing Directive, 2011/20/EC. COM/2012/0369 final. [Internet]. European Union; 2012 Jul 12 [cited 2024 Apr 13]. Available from:
https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=celex:52012PC0369
10. EudraLex – Volume 10 – Clinical trials regulation EU No 536/2014, Draft – Questions & Answers – Version 6.9, Juli 2024, Q&A 5.2 [Internet]. European Union; 2024 Jul 09 [cited 2024 Jul 28]. Available from:
https://health.ec.europa.eu/document/download/bd165522-8acf-433a-9ab1-d7dceae58112_en?filename=regulation5362014_qa_en_0.pdf
11. Forster J. Die Haftung des neuen Co-Sponsors. PharmR. 2020;1:657 - 62.
12. Schäfer C. In: Säcker FJ, Rixecker R, Oetker H, Limperg B, editors. Munich Commentary on the Civil Code. 8 ed. Munich: C.H. Beck Publishing; 2020.
13. BGH. Journal for business and banking law. 1965:795.
14. OLG Hamm. GmbHRundschau - magazine for corporate, corporate and tax law. 1992:375 - 6.
15. BGH, October 15, 1996 - VI ZR 319/95: Responsibility of the GmbH managing director for the payment of social contributions. NJW. 1997;2:130-3.
16. Bank S. Breach of duty by board members of a stock corporation. In: Patzina R, Schimmer D, Bank S, Simon-Widmann M, editors. Liability of corporate bodies. 1 ed. Munich: C.H. BECK; 2010. p. 74.
17. Krätzschmar T, Forster J. The new EU regulation on clinical trials. GWR. 2017;13:257-61.
18. Announcement from the Federal Institute for Drugs and Medical Devices, the Paul Ehrlich Institute and the Federal Ministry of Health - Non-commercial clinical trials [Internet]. European Commission; 2009 Oct 21 [cited 2024 Apr 12]. Available from:
https://www.pei.de/SharedDocs/Downloads/DE/regulation/klinische-pruefung/bekanntmachung-nicht-kommerzielle-klinische-pruefungen-211009.pdf?__blob=publicationFile&v=2.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The International Journal of Drug Regulatory affairs require a formal written transfer of copyright from the author(s) for each article published. We therefore ask you to complete and return this form, retaining a copy for your records. Your cooperation is essential and appreciated. Any delay will result in a delay in publication.
I/we have read and agree with the terms and conditions stated Page 2 of this agreement and I/we hereby confirm the transfer of all copyrights in and relating to the above-named manuscript, in all forms and media, now or hereafter known, to the International Journal of Drug Regulatory affairs, effective from the date stated below. I/we acknowledge that the IJDRA is relying on this agreement in publishing the above-named manuscript. However, this agreement will be null and void if the manuscript is not published in the IJDRA.
Download link for COPYRIGHT FORM
